Intelligent Therapeutics, Inc.

EUGENE, OR · Founded 2025 · CIK 0002136711 · Biotech · Private

Novel antibodies and antibody-like molecules for solid tumors and autoimmune diseases, plus biosimilars

inteltherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$100K
1 Form D · May 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$100,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1219Valanbio Therapeutics Inc—$121K
1220IMMUNOQ THERAPEUTICS INC.——
1221Aegle Therapeutics Corp—$6.7M
1222Intelligent Therapeutics, Inc.—$100K
1223CHEMITOPE GLYCOPEPTIDE, LLC—$100K
1224QENTOROS LLC—$605K
1225Tetraphase Biosciences——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Nathan BernsteinDirector · Executive Officer
  • Thomas EmmonsDirector · Executive Officer
  • Jason GallicDirector · Executive Officer
  • David ShearDirector
  • Michael ZvolenskyDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.